These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply. Kopylov U Aliment Pharmacol Ther; 2020 Sep; 52(5):907. PubMed ID: 32852835 [No Abstract] [Full Text] [Related]
28. [A case of Crohn's disease complicated by Guillain-Barrè syndrome during ustekinumab therapy]. Fukushima T; Nakajima K; Nozawa H; Nishino H; Sugita A; Koganei K; Futatsuki R; Yamaguchi S; Asano S; Matsushima M Nihon Shokakibyo Gakkai Zasshi; 2019; 116(4):324-329. PubMed ID: 30971669 [TBL] [Abstract][Full Text] [Related]
29. Emerging issues in the medical management of Crohn's disease. Targownik LE; Coneys JG; Dhillon AS Curr Opin Gastroenterol; 2016 Mar; 32(2):103-9. PubMed ID: 26839964 [TBL] [Abstract][Full Text] [Related]
30. Elderly-onset Crohn's disease remarkably responsive to ustekinumab: a case report. Iwamoto M; Kato K; Moriyama M Int J Colorectal Dis; 2020 Feb; 35(2):355-359. PubMed ID: 31848740 [TBL] [Abstract][Full Text] [Related]
31. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth? Liu K; Cai F; Huang J Aliment Pharmacol Ther; 2020 Oct; 52(7):1253-1254. PubMed ID: 33016544 [No Abstract] [Full Text] [Related]
32. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients. Kawalec P; Moćko P J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855 [TBL] [Abstract][Full Text] [Related]
33. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply. Biemans VBC; Hoentjen F; Pierik MJ Aliment Pharmacol Ther; 2020 Oct; 52(7):1255-1256. PubMed ID: 33016547 [No Abstract] [Full Text] [Related]
34. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. Danese S; Bonovas S; Peyrin-Biroulet L J Crohns Colitis; 2017 Oct; 11(10):1258-1266. PubMed ID: 28575273 [TBL] [Abstract][Full Text] [Related]
35. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Deepak P; Sandborn WJ Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418 [TBL] [Abstract][Full Text] [Related]
36. Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease. Adomi M; Ray A Aliment Pharmacol Ther; 2022 Apr; 55(8):1069. PubMed ID: 35362122 [No Abstract] [Full Text] [Related]
37. Ustekinumab Treatment in Crohn's Disease of Barnett Continent Intestinal Reservoir. Khan F; Shen B Inflamm Bowel Dis; 2018 Apr; 24(5):e2-e3. PubMed ID: 29688479 [No Abstract] [Full Text] [Related]
38. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Restellini S; Khanna R; Afif W Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272 [TBL] [Abstract][Full Text] [Related]
39. Update on ustekinumab for the treatment of Crohn's disease. Leung Y; Panaccione R Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262 [TBL] [Abstract][Full Text] [Related]
40. Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply. Selinger CP; Lenti MV; De Silvestri A Aliment Pharmacol Ther; 2022 Apr; 55(8):1070-1071. PubMed ID: 35362123 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]